Review article: maximising quality of life while aspiring for quantity of life in end-stage liver disease

R. A. Bhanji, E. J. Carey, K. D. Watt

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Background: With recent advances in the management of chronic liver disease and its complications, the long-term survival in cirrhosis has improved. Therefore, the number of individuals who will spend a significant proportion of their life with end-stage liver disease (ESLD) may continue to rise. Thus, more attention to quality of life (QOL) and its integration with traditional clinical endpoints is needed. Aims: Recently, there have been many studies looking at treatment outcomes and their impact on the QOL in patients with ESLD. The aim of this review was to summarise and compare the insights gained from these intervention studies and to make concise recommendations to further promote and improve QOL in this patient population. Methods: A literature search was conducted using PubMed and Web of Science. Search terms “Quality of life” “Cirrhosis” and “end-stage liver disease” were used as MeSH terms or searched in the title of the article. Results: These studies uniformly show significant improvement in health-related QOL (HRQOL) with management of malnutrition, hepatic encephalopathy and ascites. Thus, early recognition and management of these complications are keys to better serve our patients. Early involvement of palliative care also leads to improved quality of end-of-life care. Conclusions: Complications of cirrhosis including malnutrition, encephalopathy, ascites and variceal bleeding lead to a decrease in HRQOL. Assessment of HRQOL has an important implication for the patient. The findings of this review illuminate the importance of using consistent tools to accurately assess QOL in patients with ESLD.

Original languageEnglish (US)
Pages (from-to)16-25
Number of pages10
JournalAlimentary Pharmacology and Therapeutics
Volume46
Issue number1
DOIs
StatePublished - Jul 1 2017

Fingerprint

End Stage Liver Disease
Quality of Life
Fibrosis
Ascites
Malnutrition
Terminal Care
Hepatic Encephalopathy
Health
Brain Diseases
Palliative Care
PubMed
Liver Diseases
Chronic Disease
Hemorrhage
Survival
Population

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Review article : maximising quality of life while aspiring for quantity of life in end-stage liver disease. / Bhanji, R. A.; Carey, E. J.; Watt, K. D.

In: Alimentary Pharmacology and Therapeutics, Vol. 46, No. 1, 01.07.2017, p. 16-25.

Research output: Contribution to journalReview article

@article{7e5056b8a1b740449dd8b1d65fb1746f,
title = "Review article: maximising quality of life while aspiring for quantity of life in end-stage liver disease",
abstract = "Background: With recent advances in the management of chronic liver disease and its complications, the long-term survival in cirrhosis has improved. Therefore, the number of individuals who will spend a significant proportion of their life with end-stage liver disease (ESLD) may continue to rise. Thus, more attention to quality of life (QOL) and its integration with traditional clinical endpoints is needed. Aims: Recently, there have been many studies looking at treatment outcomes and their impact on the QOL in patients with ESLD. The aim of this review was to summarise and compare the insights gained from these intervention studies and to make concise recommendations to further promote and improve QOL in this patient population. Methods: A literature search was conducted using PubMed and Web of Science. Search terms “Quality of life” “Cirrhosis” and “end-stage liver disease” were used as MeSH terms or searched in the title of the article. Results: These studies uniformly show significant improvement in health-related QOL (HRQOL) with management of malnutrition, hepatic encephalopathy and ascites. Thus, early recognition and management of these complications are keys to better serve our patients. Early involvement of palliative care also leads to improved quality of end-of-life care. Conclusions: Complications of cirrhosis including malnutrition, encephalopathy, ascites and variceal bleeding lead to a decrease in HRQOL. Assessment of HRQOL has an important implication for the patient. The findings of this review illuminate the importance of using consistent tools to accurately assess QOL in patients with ESLD.",
author = "Bhanji, {R. A.} and Carey, {E. J.} and Watt, {K. D.}",
year = "2017",
month = "7",
day = "1",
doi = "10.1111/apt.14078",
language = "English (US)",
volume = "46",
pages = "16--25",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Review article

T2 - maximising quality of life while aspiring for quantity of life in end-stage liver disease

AU - Bhanji, R. A.

AU - Carey, E. J.

AU - Watt, K. D.

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Background: With recent advances in the management of chronic liver disease and its complications, the long-term survival in cirrhosis has improved. Therefore, the number of individuals who will spend a significant proportion of their life with end-stage liver disease (ESLD) may continue to rise. Thus, more attention to quality of life (QOL) and its integration with traditional clinical endpoints is needed. Aims: Recently, there have been many studies looking at treatment outcomes and their impact on the QOL in patients with ESLD. The aim of this review was to summarise and compare the insights gained from these intervention studies and to make concise recommendations to further promote and improve QOL in this patient population. Methods: A literature search was conducted using PubMed and Web of Science. Search terms “Quality of life” “Cirrhosis” and “end-stage liver disease” were used as MeSH terms or searched in the title of the article. Results: These studies uniformly show significant improvement in health-related QOL (HRQOL) with management of malnutrition, hepatic encephalopathy and ascites. Thus, early recognition and management of these complications are keys to better serve our patients. Early involvement of palliative care also leads to improved quality of end-of-life care. Conclusions: Complications of cirrhosis including malnutrition, encephalopathy, ascites and variceal bleeding lead to a decrease in HRQOL. Assessment of HRQOL has an important implication for the patient. The findings of this review illuminate the importance of using consistent tools to accurately assess QOL in patients with ESLD.

AB - Background: With recent advances in the management of chronic liver disease and its complications, the long-term survival in cirrhosis has improved. Therefore, the number of individuals who will spend a significant proportion of their life with end-stage liver disease (ESLD) may continue to rise. Thus, more attention to quality of life (QOL) and its integration with traditional clinical endpoints is needed. Aims: Recently, there have been many studies looking at treatment outcomes and their impact on the QOL in patients with ESLD. The aim of this review was to summarise and compare the insights gained from these intervention studies and to make concise recommendations to further promote and improve QOL in this patient population. Methods: A literature search was conducted using PubMed and Web of Science. Search terms “Quality of life” “Cirrhosis” and “end-stage liver disease” were used as MeSH terms or searched in the title of the article. Results: These studies uniformly show significant improvement in health-related QOL (HRQOL) with management of malnutrition, hepatic encephalopathy and ascites. Thus, early recognition and management of these complications are keys to better serve our patients. Early involvement of palliative care also leads to improved quality of end-of-life care. Conclusions: Complications of cirrhosis including malnutrition, encephalopathy, ascites and variceal bleeding lead to a decrease in HRQOL. Assessment of HRQOL has an important implication for the patient. The findings of this review illuminate the importance of using consistent tools to accurately assess QOL in patients with ESLD.

UR - http://www.scopus.com/inward/record.url?scp=85018983568&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018983568&partnerID=8YFLogxK

U2 - 10.1111/apt.14078

DO - 10.1111/apt.14078

M3 - Review article

C2 - 28464346

AN - SCOPUS:85018983568

VL - 46

SP - 16

EP - 25

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 1

ER -